Ra-223

GPTKB entity

Statements (60)
Predicate Object
gptkbp:instance_of gptkb:isotope
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:Radium-223
gptkbp:activities targeting bone metastases
gptkbp:application cancer research
treatment of bone metastases
gptkbp:class alkaline earth metals
gptkbp:clinical_trial ongoing
palliative treatment
gptkbp:color silvery-white
gptkbp:combatants 7.87 Me V
gptkbp:composed_of neutron bombardment
alkaline earth metal
gptkbp:contraindication severe renal impairment
gptkbp:cooling_system high
gptkbp:discovered_by gptkb:Frederick_Soddy
gptkbp:dissolved low
gptkbp:dosage_form 55 k Bq/kg body weight
gptkbp:duration 6 months
gptkbp:electronegativity [ Rn] 7s2
gptkbp:engine radiotherapy
gptkbp:environmental_impact radioactive waste
gptkbp:has_public_transport hazardous materials regulations
https://www.w3.org/2000/01/rdf-schema#label Ra-223
gptkbp:interacts_with other radiopharmaceuticals
gptkbp:invention patented
gptkbp:is_monitored_by regular blood tests
gptkbp:isotopes gptkb:Radium
88
135
gptkbp:lifespan 11.43 days
gptkbp:manager intravenous
gptkbp:market available in select markets
gptkbp:marketed_as gptkb:Xofigo
gptkbp:mass 223
gptkbp:melting_point 1413 ° C
700 ° C
gptkbp:mode Rn-219
gptkbp:parent gptkb:Ac-227
gptkbp:population 5.5 g/cm³
gptkbp:produced_by neutron activation
isolation from uranium ore
gptkbp:provides_information_on NCCN guidelines
gptkbp:regulatory_compliance controlled substance
gptkbp:roll_rate gptkb:0
gptkbp:safety_features radioactivity
radiation safety guidelines
gptkbp:side_effect gptkb:fandom
fatigue
nausea
radiation exposure
thrombocytopenia
neutropenia
gptkbp:storage shielded containers
gptkbp:student_enrollment cancer patients with bone metastases
gptkbp:symbol gptkb:Ra
gptkbp:type_of alpha emitter
gptkbp:used_in radiopharmaceuticals
gptkbp:water_management radioactive waste disposal
gptkbp:year_created 1923